SCHEMBL13388922

COCC1O[C@@H](O[C@@H]2C(O)[C@H](O[C@@H]3C(O)[C@H](O[C@@H]4C(O)[C@H](O[C@@H]5C(O)[C@H](O[C@@H]6C(O)[C@H](C)OC(CO)[C@H]6O)OC(CO)[C@H]5O)OC(CO[C@@H]5OC(CO)[C@@H](O)[C@H](O[C@@H]6OC(CO)[C@@H](O)[C@H](O[C@@H]7OC(CO)[C@@H](O)[C@H](O)C7O)C6O)C5O)[C@H]4O)OC(CO)[C@H]3O)OC(CO)[C@H]2O)C(O)[C@@H](OC)[C@@H]1O

nearest known ligand 0.53

Predicted protein targets (top 13)

	gene	UniProt	supporting neighbours	confidence
▸	CD209	Q9NNX6	2/20	0.53

▸	ENGASE	Q8NFI3	1/20	0.50

▸	LGALS8	O00214	1/20	0.45

▸	LGALS3	P17931	1/20	0.45

▸	LGALS4	P56470	1/20	0.45

▸	AMY2A	P04746	2/20	0.43

▸	GAA	P10253	1/20	0.42

▸	CDK1	P06493	1/20	0.41

▸	CCNB1	P14635	1/20	0.41

▸	STAT3	P40763	3/20	0.40

▸	SELL	P14151	1/20	0.40

▸	SELP	P16109	1/20	0.40

▸	AMY1A	P0DUB6	1/20	0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL13227579	1.00	CD209 (0.53)	CD209ENGASELGALS8LGALS3LGALS4
SCHEMBL15119994	1.00	CD209 (0.53)	CD209ENGASELGALS8LGALS3LGALS4
SCHEMBL14199393	0.96	CD209 (0.55)	CD209ENGASELGALS8LGALS3LGALS4
SCHEMBL15358440	0.96	CD209 (0.55)	CD209ENGASELGALS8LGALS3LGALS4
SCHEMBL9967253	0.96	CD209 (0.55)	CD209ENGASELGALS8LGALS3LGALS4
SCHEMBL17831221	0.93	CD209 (0.54)	CD209ENGASELGALS8LGALS3LGALS4
SCHEMBL14217251	0.93	CD209 (0.58)	CD209ENGASELGALS8LGALS3LGALS4
SCHEMBL14199424	0.93	CD209 (0.58)	CD209ENGASELGALS8LGALS3LGALS4
SCHEMBL15948466	0.93	CD209 (0.58)	CD209ENGASELGALS8LGALS3LGALS4
SCHEMBL15948363	0.93	CD209 (0.58)	CD209ENGASELGALS8LGALS3LGALS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-7704973-B2	Enhancing efficacy of antibodies bind to a cancer cell expressing CD20, HER2, epidermal growth factor receptor, or ganglioside 2 or 3 by orally administering a beta -glucan derived from barley having a backbone consisting of beta -(1,3) and beta -1,4) glycosidic linkages; low toxicity	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US)	2010-04-27	—	—	US	disclosed